PBS listing for first-line NSCLC therapy

The targeted therapy erlotinib has been listed on the PBS for the first-line treatment of locally advanced EGFR mutation positive non-small cell lung cancer.

Marketed as Tarceva, the drug was previously listed for patients with Stage IIIB or IV disease at later stages of their treatment but not as a first-line therapy.

In addition to the PBS listing, effective 1st January, the biomarker test to determine a patient’s EGFR mutation status is also now subsidised.

The listing was based on two Phase III clinical trials, EURTAC and OPTIMAL, which showed improved progression free survival